REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
17/01/2026
Voltar para busca
Dado oficial do USPTO
LONSURF
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
62
Atualização mais recente
18/01/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42, 44
Data de depósito
22/10/2015
Data de registro
17/01/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/03/2024
Última transação
18/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
708
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
03
Localização do titular
Tokyo, JP
Examinador
THOMAS,JULIE
Unidade examinadora
L70
Descrição da marca
The mark consists of the wording "LONSURF" in red appearing below two curvy lines, the left one in red and the right curve in red, orange and yellow.
Titulares e representantes
Titulares
TAIHO PHARMACEUTICAL CO., LTD.
TAIHO PHARMACEUTICAL CO., LTD.
Representantes
Dionne D. Heard Osha Bergman Watanabe & Burton LLP
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationsanti-cancer agentsanti-tumor agentsanti-ulcerogenic agentsagents for treatment of immunological diseasesagents for the treatment of urinary diseasesagents for painantiemetic agents; diagnostic agentspreparations and substances for medical purposes; preparations for detecting genetic predispositions for medical purposes; chemical reagents for medical or veterinary purposes; oiled paper for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; capsules sold empty for pharmaceuticals; eyepatches for medical use; ear bandages; menstruation bandages; sanitary tampons; sanitary napkins; sanitary panties; cotton for medical purposes; adhesive plasters for medical purposes; bandages for dressings; antiseptic liquid bandages; breast-nursing pads; dental adhesives; dental amalgams; dental cements; dental ceramics; dental polish; dental veneers; material for dental fillings and dental impressions; dental composite materials; dental impression materials; dental restoration compounds; sealing agents for dental purposes; lacteal flour for babies; dietary supplements for humans; dietetic foodsbiscuitjellysoup adapted for medical use; beverages for babies; food for babies
Classe 42
Scientific research for medical purposes in the field of cancertumorsulcerationimmunological diseasesurinary diseasesnauseavomiting and pain; testinginspectionresearch or evaluation of pharmaceuticals; advisoryconsultancy or information services relating to testinginspectionresearch or evaluation of pharmaceuticals and medicines; testinginspectionresearch or evaluation of medicinepharmaceutical preparationsclinical medical trials; advisoryconsultancy or information services relating to testinginspectionresearch or evaluation of medicinepharmaceutical preparationsclinical medical trials; medical and scientific researchconducting clinical trials for medicine; providing medical and scientific research information about the results of clinical trials for pharmaceutical products; design and development of computer hardware and software for use in the field of medicine; research and development of medical technology; providing information about medical and scientific research in the field of pharmaceuticals; scientific research for medical purposes in the area of cancerous diseases; conducting early evaluations in the field of new pharmaceuticals; development of pharmaceutical preparations and medicines; computer programming for the medical sector
Classe 44
Medical diagnostic testing in the fields of cancertumorsulcerationimmunological diseasesurinary diseasesnauseavomiting and pain; providing medical information relating to the treatment or prevention of cancertumorsulcerationimmunological diseasesurinary diseasesnauseavomiting and pain; medical consultation services relating to the treatment and diagnosis of cancertumorsulcerationimmunological diseasesurinary diseasesnauseavomiting and pain; medical counseling services relating to the treatment of cancertumorsulcerationimmunological diseasesurinary diseasesnauseavomiting and pain; genetic testing for medical purposesfor the diagnosis and prognosis of the expected progression of cancertumorsulcerationimmunological diseasesurinary diseasesnauseavomiting and pain; providing medical information relating to the efficacyside effectsinteractions of pharmaceuticals and medications; medical services; providing medical information; physical examination; dentistry; preparation and dispensing of medications; medical analysis services for the diagnosis of cancer; medical information services provided via the Internet; providing medical informationconsultancy and advisory services; providing information to patients in the field of administering medication; dietetic advisory services; health care services for treating cancer
Publicações
Histórico de despachos e eventos da marca no USPTO.
62 publicações encontradas
RNWL
INTERNATIONAL REGISTRATION RENEWED
25/09/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/03/2025
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
21/12/2024
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
22/11/2024
INPC
INVALIDATION PROCESSED
22/11/2024
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
05/11/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
16/10/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
16/10/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
16/10/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
16/10/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
16/10/2024
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
04/03/2024
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
04/03/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
26/02/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/02/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/02/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/02/2024
ES75
TEAS SECTION 71 & 15 RECEIVED
15/06/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/05/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/05/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/05/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
17/01/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
27/08/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/08/2021
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
27/08/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
27/08/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
27/08/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
27/08/2021
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
01/11/2019
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
11/10/2019
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
28/01/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
24/01/2019
ES7R
TEAS SECTION 7 REQUEST RECEIVED
14/12/2018
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
15/05/2018
FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
13/05/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
21/04/2017
FIMP
FINAL DISPOSITION PROCESSED
21/04/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
17/04/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
17/01/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/11/2016
PUBO
PUBLISHED FOR OPPOSITION
01/11/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/10/2016
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
26/09/2016
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
23/09/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/09/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
16/09/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
16/09/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
16/09/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
16/09/2016
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
31/08/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
31/08/2016
RFNT
REFUSAL PROCESSED BY IB
13/05/2016
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
18/03/2016
RFRR
REFUSAL PROCESSED BY MPU
18/03/2016
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/03/2016
CNRT
NON-FINAL ACTION WRITTEN
17/03/2016
MAFR
APPLICATION FILING RECEIPT MAILED
04/03/2016
DOCK
ASSIGNED TO EXAMINER
29/02/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
29/02/2016
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
26/02/2016
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
25/02/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LONSURF ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.